Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
With
Roswell Park Cancer Institute
South Texas Accelerated Research Therapeutics (START)
To assess the effect of repeated dosing with 45 mg QD PF-00299804 on the pharmacokinetics of dextromethorphan, a CYP2D6 probe, in cancer patients with advanced malignant solid tumors.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with a histologically or cytologically confirmed advanced malignant solid tumor for which there is no currently approved treatment or which is unresponsive to currently approved therapies;
Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Patients with performance status 2 could be eligible upon agreement between sponsors and investigators;
Adequate bone marrow, renal, liver and cardiac functions;
You may not be if
History of Interstitial Lung Disease (ILD).
Drugs with known CYP2D6 inhibitory effects
Drugs that are highly dependent on CYP2D6 for metabolism.